Dofetilide Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 0.125mg, 0.25mg, 0.5mg

Reference Brands: Tikosyn (USA)

Category: Heart Disorder

Dofetilide is a Class III anti-arrhythmic medication that works by selectively blocking the rapid component of the delayed rectifier potassium current in cardiac cells, thereby prolonging the cardiac action potential and refractory period. It is used for the conversion of atrial fibrillation or flutter to normal sinus rhythm and for maintenance of sinus rhythm in patients who have been converted. Because of its potential to cause QT prolongation and torsades de pointes, initiation and dose adjustment must occur under strict monitoring. Dofetilide is available in Tablets and strengths such as 0.125mg, 0.25mg, 0.5mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Dofetilide is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Dofetilide can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Dofetilide is a class III antiarrhythmic agent primarily used to convert atrial fibrillation or atrial flutter to normal sinus rhythm and to maintain sinus rhythm in patients with highly symptomatic arrhythmias lasting more than a week. By selectively blocking potassium channels in the heart, dofetilide prolongs the cardiac action potential, helping stabilize electrical activity and prevent recurrent arrhythmic episodes. Effective use of dofetilide requires careful patient selection, as it is contraindicated in individuals with certain heart conditions, renal impairment, or electrolyte imbalances.

Clinical management of dofetilide involves thorough monitoring of renal function, cardiac rhythm, and potential drug interactions to minimize risks of adverse events such as QT prolongation or torsades de pointes. Dose adjustments are often necessary based on renal clearance, and initiation typically occurs in a hospital setting to ensure patient safety. The interprofessional healthcare team, including physicians, pharmacists, and nurses, plays a critical role in optimizing therapy, educating patients, and coordinating care. By adhering to these guidelines, healthcare professionals can improve treatment outcomes, reduce complications, and provide safe, effective care for patients requiring dofetilide therapy.